Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
42 studies found for:    "Multiple system atrophy (MSA) with orthostatic hypotension"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Completed Droxidopa in Treating Patients With Neurogenic Hypotension
Conditions: Shy-Drager Syndrome;   Orthostatic Hypotension
Intervention: Drug: droxidopa
2 Recruiting The Autonomic Nervous System and Obesity
Conditions: OBESITY;   HYPERTENSION;   PURE AUTONOMIC FAILURE;   SHY-DRAGER SYNDROME
Interventions: Drug: Trimethaphan;   Drug: Pseudoephedrine
3 Not yet recruiting Water and Sudafed in Autonomic Failure
Conditions: Shy-Drager Syndrome;   Multiple System Atrophy
Interventions: Drug: Pseudoephedrine + 480 ml water;   Drug: Pseudoephedrine + 50 ml water;   Other: Placebo + 480 ml water;   Other: Placebo + 50 ml water
4 Unknown  Fipamezole in Neurogenic Orthostatic Hypotension
Conditions: Symptomatic Neurogenic Orthostatic Hypotension (NOH);   Parkinson's Disease;   Multiple System Atrophy
Interventions: Drug: Placebo;   Drug: Fipamezole
5 Recruiting PET Imaging Study of Neurochemical and Autonomic Disorders in Multiple System Atrophy (MSA)
Conditions: Multiple System Atrophy - Parkinsonian Subtype (MSA-P);   Multiple System Atrophy - Cerebellar Subtype (MSA-C)
Intervention:
6 Completed Research of Biomarkers in Parkinson Disease
Conditions: Parkinson Disease;   Multiple System Atrophy;   Progressive Supranuclear Palsy;   Huntington Disease;   Dystonia;   Diffuse Lewy Body Disease
Intervention:
7 Completed Assessment of Ambulatory Polygraphy in the Detection of Sleep Apnea in Multiple System Atrophy (SAMSA)
Conditions: Sleep Apnea Syndromes;   Multiple System Atrophy
Interventions: Device: Polysomnography;   Device: ambulatory polygraphy
8 Completed
Has Results
Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)
Conditions: Neurogenic Orthostatic Hypotension;   Non-Diabetic Autonomic Neuropathy;   Multiple System Atrophy;   Dopamine Beta Hydroxylase Deficiency
Interventions: Drug: Droxidopa;   Drug: Placebo
9 Unknown  Transcranial Duplex Scanning and Single Photon Emission Computer Tomography (SPECT) in Parkinsonian Syndromes
Conditions: Parkinson's Disease;   Parkinsonian Syndrome;   Multiple System Atrophy;   Supranuclear Palsy, Progressive;   Essential Tremor;   Vascular Parkinsonism;   Drug Induced Parkinsonism
Intervention:
10 Recruiting Defining Phenotypes of Movement Disorders :Parkinson's Plus Disorders, PD,Essential Tremor, (ET),Cortical Basal Degeneration, (CBD),Multiple Systems Atrophy (MSA), Magnetoencephalography
Conditions: Essential Tremor;   Multiple System Atrophy;   Corticobasal Degeneration;   Supranuclear Palsy, Progressive
Intervention:
11 Completed Fluoxetine in Multiple System Atrophy Patients
Condition: Multiple System Atrophy
Intervention: Drug: FLUOXETINE
12 Completed Trial of Autologous Mesenchymal Stem Cells in Patients With Multiple System Atrophy
Condition: Multiple System Atrophy
Interventions: Biological: autologous mesenchymal stem cells;   Biological: normal saline
13 Completed Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)
Condition: Multiple System Atrophy
Interventions: Drug: rasagiline mesylate;   Other: placebo
14 Terminated
Has Results
Augmenting Effects of L-DOPS With Carbidopa and Entacapone
Conditions: Parkinson Disease;   Multiple System Atrophy;   Autonomic Nervous System Diseases
Interventions: Drug: Droxidopa;   Drug: Carbidopa;   Drug: Entacapone
15 Completed Treatment of Multiple System Atrophy Using Intravenous Immunoglobulins
Condition: Multiple System Atrophy
Intervention: Drug: intravenous immunoglobulin (IVIg)
16 Not yet recruiting Study Assessing Safety and Therapeutic Activity of AFFITOPE® PD01A and PD03A in Patients With Early MSA
Conditions: Multiple System Atrophy;   Neurodegenerative Diseases
Interventions: Biological: AFFITOPE® PD01A + Adjuvant;   Biological: AFFITOPE® PD03A + Adjuvant;   Biological: Adjuvant without active component
17 Enrolling by invitation Botulinum A Toxin in Patients With Parkinson's Disease
Conditions: Parkinson's Disease;   Multiple System Atrophy;   Detrusor Overactivity
Intervention: Drug: Intravesical injection of Botulinum A toxin
18 Recruiting Investigation of the Serotoninergic System in Multiple System Atrophy: a Positron Emission Tomography (PET) Study
Condition: Multiple System Atrophy
Interventions: Radiation: PET (Positron Emission Tomography) Study;   Other: Brain MRI  (magnetic resonance imaging);   Drug: Fluoxétine / Placebo
19 Terminated Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS)
Conditions: Multiple System Atrophy;   Progressive Supranuclear Palsy
Intervention: Drug: Riluzole
20 Recruiting Identifying Biomarkers of Parkinson's Disease Using Magnetic Resonance Imaging (MRI)
Conditions: Parkinson's Disease (PD);   Parkinsonism;   Progressive Supranuclear Palsy (PSP);   Multiple System Atrophy (MSA)
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years